MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration’s final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act took effe…
MediPharm Labs has supplied product for over 10 active clinical trials, including the U.S. National Institutes of Health funded LiBBY study with the Keck School of Medicine of University of Southern …